TUSC2 and non-small cell lung carcinoma: It has also been demonstrated that exogenous expression of TUSC2 using a nanoparticle-mediated gene transfer technique sensitizes NSCLC cells to cisplatin, resulting in a 4- to 6-fold increase in the TUSC2 tumor suppressor activity.